Patients with high PSMD3 expression had worse OS, RFS, and PFS for BC and OS, and DMFS for HER2+BC, suggesting the use of PSMD3 as an unfavorable prognostic factor for BC patients. This evidence concerns the gene ERBB2 and breast cancer.